Objective
The main concern in cancer treatment is its high rate of recurrence. It may happen soon or years after treatment and it’s very hard to predict/prevent. Removing residual tumour cells is the best way to avoid recurrence, so identifying new tumour markers is the most pressing demand. We have developed SenolT, an innovative diagnostic test for the early detection and monitoring of senescent cells, which appear after chemotherapy/radiotherapy and are directly associated to cancer recurrence. SenolT detects all kinds of tumours, but we focus on pancreatic and triple negative breast (TNBC) cancers because prognosis is very poor for patients and recurrence is their main cause of mortality. Our customers will be pharmaceutical companies, so we have already contacted several of them in the sector. The initial target market will be TNBC/Pancreatic cancer patients that received chemotherapy/radiotherapy in the EU & USA. Competitors focus on liquid biopsy tests and cancer-related protein markers (expensive & slow to get results). No other companies are working in the detection of senescent cells as a diagnostic method to predict recurrence. Senolytic Therapeutics is a company that develops a new class of medicines by targeting damaged cells. Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families. Our SenolT proprietary technology will be developed and de-risked through Phase2 Clinical trials and then license the validated technologies to pharma companies, to finalise their development and bring them to the market. By 2025 we expect: A) 15% royalties’ rate on net sales with a unit price to healthcare systems of €800; B) 20% market share (70,000 people) from an expected total of TNBC/pancreatic cancer population of over 352,000 in USA & EU; C) TAM growing up to about €57 m; D) NPV of €27.2 m (10% discount rate) and an IRR of 120%; E) Cumulative EBITDA of about €44 m; F) 20 newly created jobs, mainly in R&D and sales.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- social sciences sociology demography mortality
- natural sciences biological sciences biochemistry biomolecules proteins
- social sciences economics and business business and management business models
- medical and health sciences clinical medicine oncology pancreatic cancer
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
08028 BARCELONA
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.